ArticleBlood2010
Mantle cell lymphoma activation enhances bortezomib sensitivity.
Article in Blood, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma.Leukemia · 2024Article
- Cancer Stem Cell Markers in Rhabdomyosarcoma in Children.Diagnostics (Basel, Switzerland) · 2022Article
- Drug-Tolerant Persister Cells in Cancer Therapy Resistance.Cancer research · 2022Review
- Androgen Deprivation Induces Transcriptional Reprogramming in Prostate Cancer Cells to Develop Stem Cell-Like Characteristics.International journal of molecular sciences · 2020Article
- Targeting poor proteasomal function with radioiodine eliminates CT26 colon cancer stem cells resistant to bortezomib therapy.Scientific reports · 2020Article
- Cancer Stem Cells of Diffuse Large B Cell Lymphoma Are Not Enriched in the CD45Journal of Cancer · 2020Article
- Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells.Stem cells international · 2019Review
- Interleukin-6 identified as an important factor in hypoxia- and aldehyde dehydrogenase-based gefitinib adaptive resistance in non-small cell lung cancer cells.Oncology letters · 2017Article
- Microenvironmental agonists generateBlood advances · 2017Article
- Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.Oncotarget · 2016Article
- c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.World journal of gastroenterology · 2014Review
- ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients.Molecular oncology · 2014Article
- Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cells.PloS one · 2014Article
- Effects of curcumin on stem-like cells in human esophageal squamous carcinoma cell lines.BMC complementary and alternative medicine · 2012Article
- Cancer stem cells: relevance to clinical transplantation.Current opinion in oncology · 2012Review
- Concise review: Cancer stem cells and minimal residual disease.Stem cells (Dayton, Ohio) · 2012Review
- The role of human aldehyde dehydrogenase in normal and cancer stem cells.Stem cell reviews and reports · 2011Review
- Concise review: Emerging concepts in clinical targeting of cancer stem cells.Stem cells (Dayton, Ohio) · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Patients with mantle cell lymphoma (MCL) typically respond to initial treatment but subsequently relapse. This pattern suggests that a population of MCL cells is both drug resistant and capable of clonogenic growth. The intracellular enzyme retinaldehyde dehydrogenase (ALDH) provides resistance to several toxic agents. ALDH can also identify stem cells in normal adult tissues and tumorigenic cancer stem cells in several human malignancies. We studied ALDH expression in MCL and found small populations of ALDH(+) cells that were highly clonogenic. Moreover, ALDH(+) MCL cells were relatively quiescent and resistant to a wide range of agents. Normal B cells can be activated by specific unmethylated cytosine-phosphate-guanosine (CpG) DNA motifs through toll-like receptor 9, and we found that the synthetic CpG oligonucleotide 2006 (CpG) reduced the frequency of quiescent ALDH(+) MCL cells, induced terminal plasma cell differentiation, and limited tumor formation in vitro and in vivo. Treatment with CpG also significantly enhanced the activity of the proteasome inhibitor bortezomib that was associated with induction of the unfolded protein response. Our data suggest that CpG may target clonogenic and resistant ALDH(+) cells as well as improve the activity of proteasome inhibitors in MCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.